Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
R. Asero r.asero@libero.it
Show more: Authors information and Publication historyAllergology clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy
History:Published online: 02 November 2020
Accepted: 16 March 2020
Received: 29 January 2020
Doihttp://doi.org/10.23822/EurAnnACI.1764-1489.139SummaryIn patients with Chronic Spontaneous Urticaria (CSU), low dose omalizumab maintenance therapy is effective in about one half of complete, fast responders to the drug. Omalizumab 150 mg/month was given as maintenance therapy to 21 patients with a history of severe CSU showing a complete (UAS7=0) response to the dose of 300 mg/month. After 2 months of such regimen, patients were divided into controlled (n=14; UAS7=0) and not controlled (n=7; UAS7 > 10) and ESR, CRP, total IgE, and D-dimer were measured. The two groups did not differ in any of the biomarkers considered, nor in disease duration or in pre-treatment UAS7 score. The study confirms that it is possible to halve the dose of omalizumab without any loss of efficacy in a subgroup of patients with CSU but that none of the currently available biomarkers is able to predict which patients will lose disease control following omalizumab dose reduction.
Key wordsChronic Urticaria; omalizumab; biomarkers; IgE; D-dimer; therapy.
Cite this article as:R Asero, Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?, Eur Ann Allergy Clin Immunol 2020;52(6):268-270. doi:10.23822/EurAnnACI.1764-1489.139.
FULL TEXT